The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as ...
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results